Peak
Waitlist

Peak may earn money when readers become Promise patients.

Peptide library · Growth hormone

CJC-1295 + Ipamorelin

Two different peptides combined: a growth-hormone-releasing hormone analogue and a ghrelin-receptor agonist. The premixed combination lacks direct human trials, and the two components have separate FDA compounding histories.

Last reviewed September 22, 2026

The short version

CJC-1295 + Ipamorelin combines two peptides that approach the growth-hormone axis from different receptors. CJC-1295 is a modified GHRH analogue; ipamorelin is a five-amino-acid agonist of the ghrelin receptor. General neuroendocrine biology suggests the pathways can interact, but no peer-reviewed human pharmacology study has tested the premixed combination itself.

Neither peptide is FDA-approved. CJC-1295 and ipamorelin appear differently in FDA’s compounding tables, so one status cannot be assigned to both. A licensed provider’s clinical decision does not change those FDA facts.

What it is

CJC-1295 is an engineered analogue of the first 29 amino acids of human growth-hormone-releasing factor. The form called CJC-1295 with DAC includes a chemical group designed to bind albumin; a no-DAC form is also called modified GRF(1-29). Ipamorelin is a separate synthetic pentapeptide that activates the ghrelin receptor, GHS-R1a. Neither is naturally present in the administered form.

The name describes a mixture rather than one molecule, so it has no single formula, sequence or CAS number. CJC-1295 with DAC has a reported molecular weight of 3,647.3 daltons; ipamorelin has a molecular weight of 711.86 daltons and is also called NNC 26-0161. Claims must identify which CJC form and which component a paper actually studied.

Where the research stands

The cited research does not include a human trial of the fixed combination. It includes general GH-axis reviews, class-level GHRH and ghrelin-receptor research, animal work on ipamorelin and analytical studies that detect these peptides. Those sources explain a hypothesis, not a demonstrated combined outcome.

How far the evidence has climbed

  1. Cell studiesNoneNo fixed-combination cell study cited
  2. Animal studiesNoneComponents and related agonists only
  3. Small human pilotsNoneNo human pilot of the mixture
  4. Controlled human trialsNoneNo direct combination trial
  5. FDA approvalNoNeither component is approved

Here is what selected research looked at. Each card names the actual model and does not present it as evidence for the combined prescription.

  • Scientific statement2023

    Human growth-hormone aging biology

    An Endocrine Society statement reviewed how natural growth-hormone secretion changes with age. It did not test CJC-1295, ipamorelin or their combination as a treatment.1

  • Review2021

    GHRH and ghrelin pathways

    A neuroendocrine review described how ghrelin signaling can facilitate GHRH release and affect somatostatin. That circuit is the rationale for combining pathways, not proof about this formulation.2

  • Fish2024

    Ipamorelin alone in fish

    A cichlid-fish study administered ipamorelin and measured reproductive-axis hormones and tissue findings. Fish data do not establish a human endocrine outcome.3

  • Review2026

    Unapproved-peptide safety review

    A sports-medicine review assessed the limited human safety literature for unapproved peptides including ipamorelin. It did not test the CJC-1295 and ipamorelin combination.4

  • Review2026

    Gerontology evidence gap

    A gerontology review discussed the marketed combination and looked for validation and long-term safety data. It did not identify a human trial of the fixed mixture.5

  • Analytical2018

    Unregulated product identity

    High-resolution mass spectrometry identified a modified ipamorelin analogue in seized products. It did not analyze a Promise preparation or test a clinical outcome.6

What the research can’t tell you

  • No combination trial

    The cited research does not establish human efficacy, safety or pharmacokinetics for the mixture. General pathway synergy is not clinical proof.5

  • CJC-1295 is not one fixed form

    With-DAC and no-DAC forms have different structures and expected persistence. A source about one cannot silently support the other.

  • Human safety data are scarce

    A sports-medicine review says rigorous human safety data for unapproved peptides are scarce and notes the potential for serious harm. It did not define long-term risk for this combination.4

  • Growth signaling raises a theoretical concern

    IGF-1 participates in cell growth and survival, creating a mechanism-based cancer question. That is not evidence that the combination causes cancer in people.

  • Product identity can vary

    Analytical work on seized growth-hormone secretagogues found modified peptides. It cannot describe a specific prescription, but it shows why exact identity matters.6

  • Prohibited in sport

    WADA names CJC-1295 among GHRH analogues and ipamorelin among growth-hormone secretagogues prohibited at all times.7

FDA status

Neither CJC-1295 nor ipamorelin is FDA-approved

FDA’s page, content current as of April 22, 2026, lists CJC-1295 in the withdrawn-nomination table. FDA identifies immunogenicity and peptide-characterization concerns and reports increased heart rate and systemic vasodilatory reactions in its CJC-1295 entry.8

Ipamorelin acetate is different: it appears in the withdrawn table and also remains in FDA’s safety-concern category under the 503B outsourcing-facility interim policy. FDA describes serious adverse events, including deaths, in an intravenous study; that report does not establish causation or quantify risk for another route.8

Neither peptide appears on FDA’s finalized list of additional bulk substances for patient-specific compounding.9 Promise Peptides is currently taking waitlist sign-ups. Joining is not a medical request and no prescription comes from it.

A prescription route

Promise is currently accepting waitlist signups. Joining is not a treatment request and does not result in a prescription. If treatment visits open, any treatment request would require clinical review; prescribing and pharmacy fulfillment would remain separate decisions.

  1. Start on Promise’s CJC-1295 + Ipamorelin page

    It shows what the treatment involves and its current availability.

  2. Answer the CJC-1295 + Ipamorelin questionnaire

    A licensed provider reviews health history, medicines and goals, and can decline. Not everyone qualifies.

  3. Pharmacy review is a separate step

    A prescription does not guarantee preparation or dispensing. A pharmacy must separately determine whether it can fulfill the prescription under the applicable requirements.

A prescription does not make either peptide FDA-approved or supply the missing combination trial; it reflects a clinician’s review of an individual case.

CJC-1295 + Ipamorelin at Promise

Read the treatment information and view the current waitlist.

Join the Promise waitlist

Peak may earn money when readers become Promise patients.

Joining does not guarantee future treatment availability. Availability would depend on the treatment, state, clinical review and separate pharmacy review.

Questions

Is CJC-1295 the same as ipamorelin?

No. CJC-1295 copies a GHRH signal, while ipamorelin activates the ghrelin receptor. They are separate peptides with different structures and FDA histories.

Has the combination been tested in people?

No peer-reviewed human pharmacology trial of the premixed combination is identified in the cited research. Reviews describe a rationale and a major evidence gap.5

Is ipamorelin FDA-approved?

No. It remains an unapproved substance, with a separate and more restrictive FDA table entry from CJC-1295.8

Sources

  1. Cappola AR, et al. Hormones and aging: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2023;108:1835-1874. PubMed 37326526
  2. Devesa J. The complex world of regulation of pituitary growth hormone secretion: the role of ghrelin, klotho, and nesfatins in it. Front Endocrinol. 2021;12:636403. PubMed 33776931
  3. Gouda M, et al. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish. Anim Reprod Sci. 2024;268:107550. PubMed 38996787
  4. Mendias CL, et al. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026. PubMed 41966639
  5. Mavrych V, et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging. 2026. PubMed 42021992
  6. Krug O, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018;41:1-6. PubMed 29864719
  7. World Anti-Doping Agency. The 2026 Prohibited List (S2.2.4).
  8. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026.
  9. U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A of the FD&C Act.